Literature DB >> 32563014

Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position.

Antonin Levy1, Anna D Wagner2, Cyrus Chargari3, Markus Moehler4, Marcel Verheij5, Jérôme Durand-Labrunie6, Manon Kissel6, Erick Chirat6, Pascal Burtin7, Michel Ducreux8, Valérie Boige7, Magnus Nilsson9, Narikazu Boku10, Ian Chau11, Eric Deutsch3.   

Abstract

Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective and should be prioritised in patients with metastatic disease a good performance status, and its impact on dysphagia should be determined before further interventions are planned. Regarding local treatments, the insertion of a covered self-expandable metallic stent is the most commonly used alternative, as it allows for the rapid relief of severe dysphagia. Although several randomised trials have highlighted the role of oesophageal brachytherapy, this technique is often not easily accessible. Contemporary trials are ongoing to better define the role of external radiation therapy. While awaiting these results, external radiation therapy can be considered as a second-best option for patients with a life-expectancy > 3 months. It is important to offer nutritional support and to integrate quality of life measures in the palliative management of dysphagia. This multidisciplinary international position paper aims to propose a decision-making process and highlight randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Consensus; Quality of life; Supportive care; Upper gastrointestinal cancer

Mesh:

Substances:

Year:  2020        PMID: 32563014     DOI: 10.1016/j.ejca.2020.04.032

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Local Ablative Treatment Improves Survival in ESCC Patients With Specific Metastases, 2010-2016: A Population-Based SEER Analysis.

Authors:  Hui Yang; Kunlun Wang; Yan Li; Shenglei Li; Ling Yuan; Hong Ge
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

2.  Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer.

Authors:  Swetha Sridharan; Fiona Day; Jasmin Loh; James Lynam; Joanne Smart; Brandan Holt; Hiren Mandaliya; Anthony Bonaventura; Mahesh Kumar; Jarad Martin
Journal:  Radiat Oncol       Date:  2022-09-14       Impact factor: 4.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.